{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:16:13Z","timestamp":1787026573570,"version":"build-2736575974"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>PD-L1 is one of the most critical immune checkpoint proteins, inhibiting T-cell immune responses by binding to PD-1. This study aims to validate that allicin can regulate PD-L1 expression through the IL-6\/JAK2\/STAT3 pathway, thereby inhibiting immune evasion in osteosarcoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We screened differentially expressed genes associated with prognosis using the GEO database and identified the IL-6\/JAK2\/STAT3\/PDL1 pathway through KEGG and GO enrichment analysis. We established the HOS human osteosarcoma cell line and the K7M2 mouse osteosarcoma cell line. Both cell lines were treated with allicin at concentrations of 12.5, 25, and 50 \u03bcmol\/L. Transwell, clonogenic, and scratch assays validated allicin\u2019s inhibitory effects on osteosarcoma cell growth, migration, and invasion. Western Blot assays measured expression levels of key proteins including IL-6, JAK2, STAT3, PD-L1, and phosphorylated JAK2\/STAT3. Animal models were established in Balb\/c mice and treated with allicin. Mouse clinical signs, tumor volume, and size were recorded. Tumor microenvironment and immune cell infiltration markers (CD3+, CD4+, CD8+, IFN-\u03b3, granzyme B) were analyzed via flow cytometry and immunofluorescence. Immunofluorescence and immunohistochemistry were employed to detect the expression of PD-L1, CD8, and other relevant markers in mouse tumor models, validating allicin\u2019s inhibitory effect on immune evasion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In osteosarcoma cell lines treated with allicin, the IL-6\/JAK2\/STAT3 signaling pathway was downregulated, and PD-L1 expression was significantly suppressed. In allicin-treated mice, recruitment of CD4+ and CD8+ T cells increased, IFN-\u03b3 and granzyme B expression enhanced, and tumor immune evasion was markedly inhibited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Allicin suppresses PD-L1 expression by modulating the IL-6\/JAK2\/STAT3 signaling pathway, thereby improving the tumor microenvironment and inhibiting immune evasion in osteosarcoma cells. This study demonstrates the potential of allicin as an adjunct to immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1735090","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T05:21:35Z","timestamp":1771564895000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Allicin inhibits PD-L1 through the IL-6\/JAK2\/STAT3 pathway to suppress immune evasion in osteosarcoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Rui","family":"Gong","sequence":"first","affiliation":[{"name":"First Clinical College, Shandong University of Traditional Chinese Medicine","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-min","family":"Jin","sequence":"additional","affiliation":[{"name":"First Clinical College, Shandong University of Traditional Chinese Medicine","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Cui","sequence":"additional","affiliation":[{"name":"First Clinical College, Shandong University of Traditional Chinese Medicine","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-hao","family":"Sun","sequence":"additional","affiliation":[{"name":"First Clinical College, Shandong University of Traditional Chinese Medicine","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-peng","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Affiliated Hospital of Shandong University of Traditional Chinese Medicine","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-kui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Affiliated Hospital of Shandong University of Traditional Chinese Medicine","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq276","article-title":"Osteosarcoma","author":"Ritter","year":"2010","journal-title":"Ann Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41572-022-00409-y","article-title":"Osteosarcoma","volume":"8","author":"Beird","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2103423","article-title":"New horizons in the treatment of osteosarcoma","volume":"385","author":"Meltzer","year":"2021","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01111-8","article-title":"Cancer immune evasion, immunoediting and intratumour heterogeneity","volume":"25","author":"Roerden","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","article-title":"Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion","volume":"21","author":"Jhunjhunwala","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.12.001","article-title":"RAS and PD-L1: A masters\u2019 Liaison in cancer immune evasion","volume":"47","author":"Glodde","year":"2017","journal-title":"Immunity"},{"key":"B7","doi-asserted-by":"publisher","first-page":"106287","DOI":"10.1016\/j.phrs.2022.106287","article-title":"Quercetin encapsulated in folic acid-modified liposomes is therapeutic against osteosarcoma by non-covalent binding to the JH2 domain of JAK2 Via the JAK2-STAT3-PDL1","volume":"182","author":"Jing","year":"2022","journal-title":"Pharmacol Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000798","article-title":"Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial","volume":"8","author":"Xie","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30023-1","article-title":"Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1\u20132 trial","volume":"21","author":"Davis","year":"2020","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.11.020","article-title":"Anticancer potential of garlic and its bioactive constituents: A systematic and comprehensive review","volume":"73","author":"De Greef","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/00029330-200708010-00008","article-title":"Anti-tumor effects of polybutylcyanoacrylate nanoparticles of diallyl trisulfide on orthotopic transplantation tumor model of hepatocellular carcinoma in BALB\/c nude mice","volume":"120","author":"Zhang","year":"2007","journal-title":"Chin Med J (Engl)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"802","DOI":"10.3390\/nu16060802","article-title":"Organosulfur compounds in colorectal cancer prevention and progression","volume":"16","author":"McAlpine","year":"2024","journal-title":"Nutrients"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2018.05.013","article-title":"Molecular mechanism and cytotoxicity of allicin and all-trans retinoic acid against CD44(+) versus CD117(+) melanoma cells","volume":"48","author":"Jobani","year":"2018","journal-title":"Phytomedicine"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2018.6037","article-title":"Treatment of Saos-2 osteosarcoma cells with diallyl trisulfide is associated with an increase in calreticulin expression","volume":"15","author":"Xie","year":"2018","journal-title":"Exp Ther Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.1012516","article-title":"Allicin shows antifungal efficacy against Cryptococcus neoformans by blocking the fungal cell membrane","volume":"13","author":"Li","year":"2022","journal-title":"Front Microbiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01856","article-title":"Allicin alleviates reticuloendotheliosis virus-induced immunosuppression via ERK\/mitogen-activated protein kinase pathway in specific pathogen-free chickens","volume":"8","author":"Wang","year":"2017","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0224","article-title":"Programmed cell death ligand 1 expression in osteosarcoma","volume":"2","author":"Shen","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-03195-y","article-title":"Fumarate activates the IL-6\/JAK\/STAT3 pathway by inhibiting KDM4C-mediated H3K36me3 demethylation in FH-knockdown renal cancer cells","volume":"133","author":"Xian","year":"2025","journal-title":"Br J Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00519-8","article-title":"Advancing therapy for osteosarcoma","volume":"18","author":"Gill","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B21","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12943-024-02105-9","article-title":"Advances on immunotherapy for osteosarcoma","volume":"23","author":"Yu","year":"2024","journal-title":"Mol Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13045-018-0560-1","article-title":"PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse","volume":"11","author":"Zheng","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nrc723","article-title":"Natural products in cancer chemotherapy: past, present and future","volume":"2","author":"Mann","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"111634","DOI":"10.1016\/j.jep.2018.12.008","article-title":"Allicin enhances antimicrobial activity of macrophages during Mycobacterium tuberculosis infection","volume":"243","author":"Dwivedi","year":"2019","journal-title":"J Ethnopharmacol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e2402801","DOI":"10.1002\/advs.202402801","article-title":"Allicin\u2013Decorated feO(1-x)OH nanocatalytic medicine for fe(2+)\/fe(3+) cycling\u2013Promoted efficient and sustained tumor regression","volume":"11","author":"Jie","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"9162","DOI":"10.3390\/ijms22179162","article-title":"Allicin may promote reversal of T-cell dysfunction in periodontitis via the PD-1 pathway","volume":"22","author":"Patil","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-020-03919-z","article-title":"Allicin can suppress the activity of vascular endothelial cells probably by regulating JAK2\/STAT3 pathway","volume":"476","author":"Sun","year":"2021","journal-title":"Mol Cell Biochem"},{"key":"B29","doi-asserted-by":"publisher","first-page":"106012","DOI":"10.1016\/j.intimp.2019.106012","article-title":"Breast cancer cells promote CD169(+) macrophage-associated immunosuppression through JAK2-mediated PD-L1 upregulation on macrophages","volume":"78","author":"Jing","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam7729","article-title":"Oncogenic JAK2(V617F) causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms","volume":"10","author":"Prestipino","year":"2018","journal-title":"Sci Transl Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126022","article-title":"IL-6\/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion","volume":"129","author":"Chan","year":"2019","journal-title":"J Clin Invest"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-0118","article-title":"Combined blockade of IL6 and PD-1\/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment","volume":"78","author":"Tsukamoto","year":"2018","journal-title":"Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010612","article-title":"Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6\/Jak\/Stat3 in PD-L1-high lung cancer","volume":"13","author":"Jeong","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-311585","article-title":"IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer","volume":"67","author":"Mace","year":"2018","journal-title":"Gut"},{"key":"B35","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41571-022-00601-9","article-title":"Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics","volume":"19","author":"Yamaguchi","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12964-025-02073-7","article-title":"A novel therapeutic approach targeting PD-L1 in HNSCC and bone marrow-derived mesenchymal stem cells hampers pro-metastatic features in vitro: perspectives for blocking tumor-stroma communication and signaling","volume":"23","author":"Ferrara","year":"2025","journal-title":"Cell Commun Signal"},{"key":"B37","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","article-title":"Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches","volume":"10","author":"Tufail","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B38","doi-asserted-by":"publisher","first-page":"217620","DOI":"10.1016\/j.canlet.2025.217620","article-title":"Irreversible electroporation combined with PD-L1\/IL-6 dual blockade promotes anti-tumor immunity via cDC2\/CD4(+)T cell axis in MHC-I deficient pancreatic cancer","volume":"617","author":"Wu","year":"2025","journal-title":"Cancer Lett"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06199-x","article-title":"CD4(+) T cell-induced inflammatory cell death controls immune-evasive tumours","volume":"618","author":"Kruse","year":"2023","journal-title":"Nature"},{"key":"B40","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41586-019-1671-8","article-title":"MHC-II neoantigens shape tumour immunity and response to immunotherapy","volume":"574","author":"Alspach","year":"2019","journal-title":"Nature"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/jop.13525","article-title":"Tumor immune microenvironment in odontogenic carcinomas: Evaluation of the therapeutic potential of immune checkpoint blockade","volume":"53","author":"Oh","year":"2024","journal-title":"J Oral Pathol Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"113683","DOI":"10.1016\/j.biopha.2022.113683","article-title":"Role of interferon-gamma (IFN-\u03b3) and IFN-\u03b3 receptor 1\/2 (IFN\u03b3R1\/2) in regulation of immunity, infection, and cancer development: IFN-\u03b3-dependent or independent pathway","volume":"155","author":"Ding","year":"2022","journal-title":"BioMed Pharmacother"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1190333","article-title":"Dysregulation in IFN-\u03b3 signaling and response: the barricade to tumor immunotherapy","volume":"14","author":"Han","year":"2023","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1628014","article-title":"Granzyme B and melittin in cancer immunotherapy: molecular mechanisms and therapeutic perspectives in head and neck cancers","volume":"16","author":"Majchrzak","year":"2025","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000291","article-title":"Granzyme B PET imaging of immune-mediated tumor killing as a tool for understanding immunotherapy response","volume":"8","author":"LaSalle","year":"2020","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1735090\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T05:21:37Z","timestamp":1771564897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1735090\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2026.1735090"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1735090","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"article-number":"1735090"}}